Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational

Kidney Disease Biomarkers

NCT00255398
Conditions
Kidney Disease, Glomerular Disease, Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Collapsing Glomerulopathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Urinary Tract Infections, Recurrent Urinary Tract Infection
Interventions
Chlorhexidine, Sterile Water
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years to 89 Years · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Stricture Urethra
Interventions
Urotronic Drug Coated Balloon (DCB)
Combination Product
Lead sponsor
Urotronic Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Brooklyn Park, Minnesota
Active, not recruiting Phase 3 Interventional Results available

Savolitinib vs. Sunitinib in MET-driven PRCC.

NCT03091192
Conditions
Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms, Kidney Diseases, Neoplasms by Site, Enzyme Inhibitors, Protein Kinase Inhibitors
Interventions
Savolitinib, Sunitinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
8
States / cities
La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 74 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Renal Artery Obstruction
Interventions
Stenting: Renal Artery
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Chronic Kidney Disease
Interventions
Self-management of BP medications, Self-monitoring of home BP
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Adult Rhabdomyosarcoma, Lung Metastases, Metastatic Ewing Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Stage IV Adult Soft Tissue Sarcoma, Stage IV Wilms Tumor, Stage V Wilms Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
intensity-modulated radiation therapy
Radiation
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 29 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 4 more
Conditions
Kidney Stone
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 3 Interventional Results available

Phase 3 Study of SNF472 for Calciphylaxis

NCT04195906
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy
Interventions
Experimental: SNF472, Placebo Comparator: Placebo, Experimatenl SNF472 (Open-label)
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • El Centro, California • Escondido, California + 34 more
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma, Small-cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions
GEN-011, IL-2, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more
Conditions
Hypophosphatemia, X-linked Hypophosphatemia, Renin-angiotensin System, Left Ventricular Hypertrophy
Interventions
Ang II and Ang-(1-7), FGF23 and klotho
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 24 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Advanced Solid Tumor, Lymphoma
Interventions
DS-3078a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Active, not recruiting Not applicable Interventional

Plant-based Diet for Kidney Transplant Recipients

NCT06186843
Conditions
Kidney Disease, Chronic, Transplant Complication, Hypertension, Diabetes Mellitus, Metabolic Syndrome, Inflammation, Kidney Transplant Failure, Dietary Habits
Interventions
Plant-based diet
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
High-Risk Non-Muscle-Invasive Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec
Drug
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
65
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 57 more
Recruiting Not applicable Interventional

Decision Aid (DA) for Renal Patients

NCT05387863
Conditions
Kidney Tumor, Renal Cancer
Interventions
Decision Aid (DA) Web Tool, Institutional Pamphlet
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Obesity
Interventions
Relaxation methods
Behavioral
Lead sponsor
Edward Hines Jr. VA Hospital
Federal
Eligibility
18 Years to 88 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Hines, Illinois
Conditions
Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 70 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Ithaca, New York • New York, New York + 2 more
Conditions
End Stage Renal Disease
Interventions
Rituxan
Biological
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Metastatic Renal Cell Carcinoma
Interventions
PF-04856884, Axitinib (AG-013736)
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
28
States / cities
Scottsdale, Arizona • Tucson, Arizona • Aurora, Colorado + 17 more
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Tolterodine ER
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more
Not yet recruiting Phase 4 Interventional

REDUCER Trial (TXA in Urethroplasty)

NCT07501884
Conditions
Urethral Stricture, Urethral Diseases
Interventions
Tranexamic Acid, Urethroplasty
Drug · Procedure
Lead sponsor
Amjad Alwaal, MD, MSc, FRCSC, FACS
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Kidney Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Los Angeles, California • New York, New York